Short Interest in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) Decreases By 53.2%

Key Points

• Short interest in Nanobiotix S.A. decreased by 53.2% in September, dropping to 11,000 shares from 23,500 shares in August.
• Analysts maintain a Moderate Buy rating on Nanobiotix, with a price target of $11.00, and have noted a recent buy rating issued by HC Wainwright.
• A hedge fund, Jane Street Group, has recently acquired a new stake in Nanobiotix, purchasing over 23,000 shares valued at approximately $73,000.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totaling 11,000 shares, a drop of 53.2% from the August 31st total of 23,500 shares. Based on an average trading volume of 26,300 shares, the short-interest ratio is presently 0.4 days. Based on an average trading volume of 26,300 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Leerink Partners set a $14.00 price objective on Nanobiotix in a research note on Thursday, September 18th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.00.

Nanobiotix Stock Performance

Nanobiotix stock opened at $19.88 on Friday. Nanobiotix has a 1-year low of $2.76 and a 1-year high of $21.12. The stock's fifty day moving average is $10.00 and its two-hundred day moving average is $6.13.

Institutional Trading of Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Jane Street Group LLC purchased a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,283 shares of the company's stock, valued at approximately $73,000. 38.81% of the stock is owned by institutional investors.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.